Abstract
Features of anti-hypertensive therapy amlodipiny at patients with the arterial hypertonia (AH) with comorbid pathology – kislotozavisimy diseases (KZZ), accepting омепразол, depending on genetic features of the patient are studied and analysed. It is shown that a certain genetic polymorphism of an isoenzyme of P450 3A4 cytochrome can shift a metabolism of an omeprazol towards P450 3A4 cytochrome and promote more expressed oppression of activity of this enzyme. Depending on rate of a metabolism at the sick AG and KZZ receiving a combination of an amlodipin and an omeprazol various anti-hypertensive effect of an amlodipin can be observed. Reliable differences in dynamics of indicators of daily monitoring of the arterial blood pressure (ABP) at sick AG - slow metabolizator and sick AG – fast and intermediate metabolizator are received. Decrease of the activity of an isoenzyme of P450 3A4 cytochrome at patients - slow metabolizator leads to retardation of a metabolism of an amlodipin and, as a result, to rising of its concentration in a blood plasma that is clinically shown by more expressed anti-hypertensive effect.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
